Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureCatherine A. Reznikoff, Somdatta Sarkar, K. Jülicher, Melissa S. Burger, J A Puthenveettil, David Frazier Jarrard, Michael A. Newton
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Pathways of development and progression in bladder cancer
1993
Biology of disease—urinary bladder cancer
1994
Molecular genetics of bladder cancer
1995
Genetic studies and molecular markers of bladder cancer (Review)
10.1002/(sici)1098-2388(199709/10)13:5<319::aid-ssu5>3.0.co;2-g · 1997
Unresolved referenced work
Kept as external metadata until matched
Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder
1988
10.1007/978-1-4471-1362-1
10.1007/978-1-4471-1362-1
Unresolved referenced work
Kept as external metadata until matched
Systemic chemotherapy of transitional cell carcinoma of the urothelium
10.1002/(sici)1098-2388(199709/10)13:5<365::aid-ssu11>3.0.co;2-m · 1997
Combined-modality therapy for bladder cancer
1997
Clonal origin of bladder cancer
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1056/nejm199203123261104 · 1992
Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of p53 and retinoblastoma proteins
10.1016/s0022-5347(01)65550-2 · 1996
Mosaicism in human epithelium
10.1016/s0022-5347(01)67507-4 · 1995
Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin CB 48-month follow-up
10.1159/000282849 · 1996
Natural history of superficial bladder tumors B 10- to 20-year follow-up of treated patients
10.1007/bf02201977 · 1997
The treated natural history of high risk superficial bladder cancer
10.1097/00005392-199707000-00017 · 1997
Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder
10.1016/s0022-5347(01)66043-9 · 1996
Two molecular pathways to transitional cell carcinoma of the bladder
1994
A molecular genetic model of human bladder cancer pathogenesis
1996
Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer
10.1016/s0022-5347(17)35014-0 · 1994
Cytogenetics of bladder cancer
10.1016/s0165-4608(96)00295-6 · 1997
Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization
10.1002/gcc.2870120309 · 1995
Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization
1997
Genetic alterations in primary bladder cancers and their metastases
1998
Accumulated allelic losses in the development of invasive urothelial cancer
10.1002/ijc.2910530409 · 1993
Allelotype of human bladder cancer
1994
Molecular genetic alterations in superficial and locally advanced human bladder cancer
1991
Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder
1996
Overcoming cellular senescence in human cancer pathogenesis
10.1101/gad.12.2.163 · 1998
Fluorescence in situ hybridization deletion mapping at 4p16.3 in bladder cancer cell lines refines the localization of the critical interval to 30 kb
10.1002/(sici)1098-2264(199610)17:2<108::aid-gcc6>3.0.co;2-9 · 1996
Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer
1991
Deletion mapping implicates two tumor suppressor genes on chromosomes 8p in the development of bladder cancer
1996
Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer
1997
c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization
1995
Evidence for two bladder cancer suppressor loci on human chromosome 9
1993
Preliminary mapping of the deleted region of chromosome 9 in bladder cancer
1993
Role of chromosome 9 in human bladder cancer
1993
Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors
1994
Detailed deletion mapping of chromosome 9q in bladder cancer
1995
Evidence for two tumor suppresor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations
1996
Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
10.1002/(sici)1097-0142(19980215)82:4<708::aid-cncr14>3.0.co;2-1 · doi-reference
Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer
10.1093/jnci/89.10.724 · doi-reference
Telomerase activity
10.1073/pnas.94.25.13677 · doi-reference
Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids
10.1016/0165-4608(92)90213-r · doi-reference
Nonrandom chromosome losses in tumorigenic revertants of hybrids between isogenic immortal and neoplastic human uroepithelial cells
10.1007/bf01233620 · doi-reference
Role of SV40 T antigen binding to pRB and p53 in multistep transformation in vitro of human uroepithelial cells
10.1093/carcin/14.11.2297 · doi-reference
Addressing the significance of chromosome-loss data
10.1002/sim.4780130805 · doi-reference
In vitro radiation-induced neoplastic progression of low-grade uroepithelial tumors
10.2307/3578850 · doi-reference
Neoplastic transformation of SV40-immortalized human urinary tract epithelial cells by in vitro exposure to 3-methylcholanthrene
10.1093/carcin/9.8.1427 · doi-reference
Allelic 3p deletions in high-grade carcinomas after transformation in vitro of human uroepithelial cells
10.1002/gcc.2870030505 · doi-reference
Minimal deletion of 3p13614.2 associated with immortalization of human uroepithelial cells
10.1002/(sici)1098-2264(199801)21:1<39::aid-gcc6>3.0.co;2-9 · doi-reference
The INK4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53
10.1016/s0092-8674(00)81400-2 · doi-reference
Tumor suppression at the mouse er locus mediated by the alternative reading frame product p19ARF
10.1016/s0092-8674(00)80452-3 · doi-reference
20q gain associates with immortalization
10.1038/sj.onc.1200868 · doi-reference
Immortalization of human uroepithelial cells by human papillomavirus 16 E6 or E7
10.1002/roi.2970030623 · doi-reference
Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells
10.1002/gcc.2870040210 · doi-reference
p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer
10.1016/0046-8177(94)90096-5 · doi-reference
The epidermal growth factor receptor and the prognosis of bladder cancer
10.1002/1097-0142(19900401)65:7<1619::aid-cncr2820650728>3.0.co;2-q · doi-reference
Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder
10.1016/0046-8177(95)90086-1 · doi-reference
Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder
10.1038/bjc.1995.14 · doi-reference
Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer
10.1093/jnci/84.16.1256 · doi-reference
Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer
10.1007/bf01202728 · doi-reference
Overexpression of p53 protein and its significance for recurrent progressive bladder tumours
10.1046/j.1464-410x.1996.09386.x · doi-reference
The prognostic value of p53 in superficially infiltrating transitional cell carcinoma
10.3109/00365599509180032 · doi-reference
Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer
10.1016/s0090-4295(99)80216-7 · doi-reference
Immunohistochemical determination of p53 overexpression
10.1007/bf00942045 · doi-reference
p53 expression compared with other prognostic factors in OMS Grade-1 Stage-Ta transitional cell carcinoma of the bladder
10.1159/000480864 · doi-reference
p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer
10.1016/s0022-5347(01)64939-5 · doi-reference
Correlation of allelic loss of the p53 gene and tumor grade, stage, and malignant progression in bladder cancer
10.1111/j.1442-2042.1997.tb00144.x · doi-reference
Accumulation of nuclear p53 and tumor progression in bladder cancer
10.1056/nejm199411103311903 · doi-reference
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma
10.1093/jnci/85.1.53 · doi-reference
Interaction between the retinoblastoma protein and the oncoprotein mdm2
10.1038/375694a0 · doi-reference
mdm2 promotes the rapid degradation of p53
10.1038/387296a0 · doi-reference
Effect of p21(WAF1/CIP1) expression on tumor progression in bladder cancer
10.1093/jnci/90.14.1072 · doi-reference
Chromosomal changes during progression of transitional cell carcinoma of the bladder and delineation of the amplified interval on chromosome arm 8q
10.1002/(sici)1098-2264(199810)23:2<167::aid-gcc10>3.0.co;2-l · doi-reference
Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells
10.1101/gad.8.18.2227 · doi-reference
Myc activates telomerase
10.1101/gad.12.12.1769 · doi-reference
Positional cloning of ZNF217 and NABC1
10.1073/pnas.95.15.8703 · doi-reference
Prevalence and clinical significance of HER-2/NEU, p53 and RB expression in primary superficial bladder cancer
10.1016/s0022-5347(01)66198-6 · doi-reference
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
10.1038/bjc.1991.211 · doi-reference